MENU
EMBC
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

EMBC stock forecast, quote, news & analysis

Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes... Show more

Interact to see
Advertisement
A.I.Advisor
published price charts
EMBC
Daily Signal:
Gain/Loss:
A.I.Advisor
a Summary for EMBC with price predictions
Oct 22, 2026

Aroon Indicator for EMBC shows an upward move is likely

EMBC's Aroon Indicator triggered a bullish signal on October 22, 2026. Tickeron's A.I.dvisor detected that the AroonUp green line is above 70 while the AroonDown red line is below 30. When the up indicator moves above 70 and the down indicator remains below 30, it is a sign that the stock could be setting up for a bullish move. Traders may want to buy the stock or look to buy calls options. A.I.dvisor looked at 147 similar instances where the Aroon Indicator showed a similar pattern. In 117 of the 147 cases, the stock moved higher in the days that followed. This puts the odds of a move higher at 80%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on October 12, 2026. You may want to consider a long position or call options on EMBC as a result. In 58 of 78 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 74%.

The Moving Average Convergence Divergence (MACD) for EMBC just turned positive on October 13, 2026. Looking at past instances where EMBC's MACD turned positive, the stock continued to rise in 31 of 40 cases over the following month. The odds of a continued upward trend are 77%.

Following a +6.85% 3-day Advance, the price is estimated to grow further. Considering data from situations where EMBC advanced for three days, in 188 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

Bearish Trend Analysis

The RSI Indicator has been in the overbought zone for 1 day. Expect a price pull-back in the near future.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 6 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where EMBC declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.

EMBC broke above its upper Bollinger Band on October 22, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 16 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 20 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (-0.634) is normal, around the industry mean (4.961). P/E Ratio (4.573) is within average values for comparable stocks, (37.232). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (4.143). Dividend Yield (0.006) settles around the average of (0.005) among similar stocks. P/S Ratio (0.300) is also within normal values, averaging (56.876).

The Tickeron Price Growth Rating for this company is 37 (best 1 - 100 worst), indicating steady price growth. EMBC’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is 91 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. EMBC’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

A.I.Advisor
published Dividends

EMBC paid dividends on September 15, 2026

Embecta Corp EMBC Stock Dividends
А dividend of $0.01 per share was paid with a record date of September 15, 2026, and an ex-dividend date of August 27, 2026. Read more...
A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are Intuitive Surgical (NASDAQ:ISRG), Align Technology (NASDAQ:ALGN).

Industry description

Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.

Market Cap

The average market capitalization across the Pharmaceuticals: Other Industry is 9.45B. The market cap for tickers in the group ranges from 126 to 156.8B. ISRG holds the highest valuation in this group at 156.8B. The lowest valued company is HGYMF at 126.

High and low price notable news

The average weekly price growth across all stocks in the Pharmaceuticals: Other Industry was 1%. For the same Industry, the average monthly price growth was -4%, and the average quarterly price growth was 7%. PLSE experienced the highest price growth at 16%, while BNGO experienced the biggest fall at -14%.

Volume

The average weekly volume growth across all stocks in the Pharmaceuticals: Other Industry was 5%. For the same stocks of the Industry, the average monthly volume growth was 6% and the average quarterly volume growth was 13%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 59
P/E Growth Rating: 53
Price Growth Rating: 53
SMR Rating: 81
Profit Risk Rating: 94
Seasonality Score: 11 (-100 ... +100)
Aroon Indicator for EMBC shows an upward move is likely